Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020505 (
hyperphagia
)
6,116
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Antagonism of the histamine (H2) receptor reduces antinociception induced by naloxone-resistant foot-shock, naloxone-sensitive foot-shock, and morphine with a rank-order potency similar to their H2 antagonism. The antimetabolic glucose analog 2-deoxy-
D-glucose
(2DG) produces antinociceptive and hyperphagic responses that dissociate from each other and are in part mediated by opioid systems. The present study determined the effects of the brain-penetrating H2 receptor antagonist zolantidine (ZOL) on 2DG antinociception on the tail-flick and jump tests, as well as on 2DG
hyperphagia
, in rats. ZOL (0.01-1 mg/kg) potentiated the antinociceptive responses induced by a moderate (450 mg/kg) dose of 2DG, but had lesser effects upon antinociception induced by a lower (100 mg/kg) 2DG dose. ZOL itself slightly increased jump thresholds, but not tail-flick latencies. Combinations of ZOL and 2DG produced supraadditive antinociception, even though ZOL failed to significantly shift the 2DG dose-response curve to the left. In contrast, ZOL failed to alter basal intake or 2DG
hyperphagia
, supporting previous evidence implicating the H1 but not the H2 receptor in these effects. These results further dissociate the antinociceptive and hyperphagic effects of 2DG, and also support previous results indicating both pro- and antinociceptive roles for H2 receptors.
...
PMID:Potentiation of 2-deoxy-D-glucose antinociception, but not hyperphagia by zolantidine, a histamine (H2) receptor antagonist. 134 37
Inhibition of deprivation-induced intake by naloxone was significantly enhanced by the 5-hydroxytryptamine3 (5-HT3) antagonist ICS-205,930. Interactions between naloxone and either the general 5-HT antagonist methysergide or the 5-HT2 antagonist ritanserin or ketanserin produced smaller effects. The present study evaluated whether 2-deoxy-
D-glucose
(2DG, 400 mg/kg)
hyperphagia
was affected by methysergide (0.5-5 mg/kg), ritanserin (0.25-2.5 mg/kg), or ICS-205,930 (0.5-5 mg/kg) alone or in combination with naltrexone (0.25 and 2.5 mg/kg). Only ICS-205,930 stimulated spontaneous intake for up to 4 h in the light cycle. Only ritanserin (1.25 mg/kg) transiently reduced 2DG
hyperphagia
. The dose-dependent decreases in 2DG
hyperphagia
by naltrexone were significantly enhanced by the dose range of ICS-205,930. The inhibition of 2DG
hyperphagia
by the low naltrexone dose was enhanced by methysergide (5 mg/kg) and ritanserin (1.25 mg/kg). These data suggest that the 5-HT3 receptor primarily interacts with opioid systems to modulate 2DG
hyperphagia
and that one possible locus of interaction is in the caudal brainstem.
...
PMID:Naltrexone, serotonin receptor subtype antagonists, and glucoprivic intake: 1. 2-Deoxy-D-glucose. 151 47
Opiate antagonist inhibition of deprivation-induced intake and 2-deoxy-
D-glucose
(2DG)
hyperphagia
is significantly enhanced by the 5-hydroxytryptamine3 (5-HT3) antagonist, ICS-205,930. Interactions between opiate antagonists and either 5-HT or 5-HT2 antagonists produced smaller effects. The present study evaluated whether insulin (5 U/kg)
hyperphagia
was affected by methysergide (0.5-5 mg/kg), ritanserin (0.25-2.5 mg/kg), and ICS-205,930 (0.5-5 mg/kg) alone or in combination with naltrexone (2.5-10 mg/kg). Whereas ICS-205,930 stimulated insulin
hyperphagia
across the 6-h time course, ritanserin and, to a lesser degree, methysergide reduced insulin
hyperphagia
. Naltrexone marginally (19-33%) reduced insulin
hyperphagia
. Pairing naltrexone with either ICS-205,930 or ritanserin significantly suppressed insulin
hyperphagia
after 2 h. Pairing naltrexone with each of the serotonin antagonists significantly enhanced insulin
hyperphagia
after 4 and 6 h. These data suggest that 5-HT2 and 5-HT3 receptor subtypes interact with opioid systems to modulate insulin
hyperphagia
. Given that central insulin reduces food intake and body weight, the interaction between serotonergic and opioid systems may occur peripherally.
...
PMID:Naltrexone, serotonin receptor subtype antagonists, and glucoprivic intake: 2. Insulin. 151 48
The effect of various doses of 2-deoxy-
D-glucose
(2-DG) on food intake in rats fed either a medium fat diet with a moderate carbohydrate content (MF-rats) or a carbohydrate-free high fat diet (HF-rats) was tested. Injections were given intraperitoneally either in the middle of the bright phase or 1 h after onset of the dark phase. During the light phase 2-DG induced a transient
hyperphagia
in both HF- and MF-rats, but the
hyperphagia
was somewhat less pronounced in HF-rats. During the dark phase 2-DG produced a
hyperphagia
in the MF-rats and a long-term hypophagia in the HF-rats. Since 2-DG elicited feeding in HF-rats during the light phase, the feeding response to 2-DG not only reflects hunger for carbohydrate as previously suggested but also seems to produce hunger for energy.
...
PMID:Effects of 2-deoxy-D-glucose on food intake of rats are affected by diet composition. 161 56
Sugar absorption by the biliary ductular epithelium under steady-state conditions was examined using isolated perfused rat liver. The test sugar and mannitol (as a putative marker of paracellular entry) were added to the glucose-free recirculating perfusate each at a concentration of 5 mmol/L, and apparent active biliary ductular absorption equated with the change in concentration of the test sugar relative to that of mannitol. A metabolizable hexose (
D-glucose
), pentose (D-xylose), and three nonmetabolizable hexoses (alpha-methyl-
glucoside
, 3-o-methyl-glucose, and L-glucose) were used. All five monosaccharides were well absorbed at constant rates for 2 hours with apparent rates of absorption (mumol.kg body weight-1.min-1, mean +/- SE) of
D-glucose
, 0.24 +/- 0.01; L-glucose, 0.20 +/- 0.02; 3-o-methyl-glucose, 0.19 +/- 0.02; alpha-methyl-
glucoside
, 0.16 +/- 0.03; and D-xylose, 0.10 +/- 0.04. The addition of phloridzin to the perfusate inhibited
D-glucose
absorption in part but did not inhibit L-glucose absorption. When perfusate Na+ was replaced by N-methylglucamine, the bile-plasma ratio of mannitol remained unchanged, as did the apparent absorption rate of
D-glucose
and 3-o-methyl-glucose. In contrast, absorption of L-glucose and alpha-methyl-D-
glucoside
gradually ceased. The addition of 15 mmol/L glucose to the perfusate caused decreased bile flow and increased taurocholate concentration in bile, suggesting that glucose absorption by the biliary ductules induced water reabsorption. It is concluded that sugars are absorbed by the biliary ductular system by Na(+)-dependent and Na(+)-independent transport systems, the substrate affinities of which differ from those reported for apical membrane hexose transport systems in renal tubular and intestinal epithelia. Ductular absorption of solutes such as glucose that enter bile passively may have biological use, because ductular absorption decreases the concentration of substrates for bacterial growth in gallbladder bile. On the other hand, ductular absorption of solutes induces reabsorption of biliary water, resulting in decreased bile flow; this might contribute to cholestasis during prolonged
hyperalimentation
with solutions containing glucose.
...
PMID:Sugar absorption by the biliary ductular epithelium of the rat: evidence for two transport systems. 158 53
Chronic diabetes enhances intestinal absorption of glucose and induces
hyperphagia
. We examined the enhanced intestinal absorption of glucose in ad libitum-fed rats with streptozocin-induced diabetes mellitus and compared these results with those obtained from pair-fed diabetic animals. Maximal transport capacity (Vmax) and carrier affinity (K0.5) were determined by measuring jejunal and ileal short circuit current (Isc) responses to varying concentrations of 3-O-methyl-D-glucopyranose and
D-glucose
. Pair-fed diabetic animals maintained the same body weight as animals fed ad libitum, although ad libitum-fed diabetic rats had an increased oral chow intake. Age-matched control rats maintained a constant jejunal and ileal Vmax and K0.5 throughout the study. Diabetic rats fed ad libitum demonstrated an enhanced Vmax and K0.5 in both jejunum and ileum. Pair feeding diabetic animals further enhanced jejunal Vmax while lowering jejunal K0.5 levels. In contrast, pair feeding diabetic animals delayed and blunted changes in ileal Vmax and prevented changes in ileal K0.5. In conclusion, signals other than those of
hyperphagia
regulate kinetic changes in glucose absorption during diabetes mellitus. Furthermore, these changes have differing effects on jejunum and ileum.
...
PMID:Adaptation of intestinal glucose transport in rats with diabetes mellitus occurs independent of hyperphagia. 178 96
This study investigated the effect of fasting, self-selected meals and isocaloric oral glucose and fat meals and intravenous (i.v.) feeding on plasma zinc concentrations in men. Plasma zinc remained stable when volunteers fasted all day, but self-selected meals and 600 kCal of
dextrose
or fat emulsion caused significantly reduced plasma zinc concentrations [mean (SD) 12.1 (1.4), 12.3 (0.6) and 12.2 (0.7) mumol/L at 1400 h, respectively, compared with a fasting level of 13.9 (1.6) mumol/L at 0800 h, P less than 0.05]. In patients undergoing intravenous
hyperalimentation
, plasma zinc decreased from 12.0 (1.4) mumol/L at 0800 h to 10.0 (1.1) mumol/L at 1400 h [mean (SD), P less than 0.01]. These data show that both enteral and i.v. feeding cause a decline in plasma zinc and that glucose alone is not responsible for this post-prandial fall since ingestion of isocaloric amounts of glucose or fat have a similar effect.
...
PMID:Effect of fasting, self-selected and isocaloric glucose and fat meals and intravenous feeding on plasma zinc concentrations. 195 45
The increased food intake in the rat during the first two hours of the dark cycle was significantly inhibited by central pretreatment with either the selective kappa opioid antagonist, nor-binaltorphamine (NorBNI, 20 micrograms, i.c.v., 53-54%) or naltrexone (NTX, 20 micrograms, i.c.v., 47-60%). Short-term (2 h) intake of a high-fat diet was significantly inhibited by central NorBNI (1-20 micrograms, 33-79%) and NTX (20 micrograms, 47-51%).
Hyperphagia
induced by the anti-metabolic glucose analogue, 2-deoxy-
D-glucose
was significantly inhibited by central NorBNI (20 micrograms, 40-68%) and NTX (20 micrograms, 28-69%). These data suggest that the kappa receptor subtype, in addition to other opioid receptor subtypes, influence these forms of feeding behavior.
...
PMID:Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphamine. 196 62
Previous observations from this laboratory indicate that, during growth, the
hyperphagia
of the male genetically obese Zucker rat reaches a peak or "breakpoint" and then declines. To examine the effect of dietary macronutrient content on the course of
hyperphagia
, groups of male lean and obese rats were maintained from 5-28 weeks of age on powdered chow, or isocaloric diets (3.6 kcal/g) containing 72% of calories as corn oil,
dextrose
, or soy isolate protein (n = 5 lean and obese rats/diet). On chow,
hyperphagia
was maintained at a level of 7-8 g above lean control intake until a "breakpoint" was reached at 17 weeks, and obese intake declined to lean control level. On the fat diet,
hyperphagia
was increased to 10 g/day when a breakpoint was reached at 8 weeks. On the
dextrose
and protein diets,
hyperphagia
at a level of 3-4 g/day reached breakpoints at weeks 18 and 16, respectively. On all diets, the intakes of obese rats were precisely equal to the intakes of lean control rats by weeks 19-20. These data show that the magnitude and duration of
hyperphagia
in the developing obese rat are influenced by diet composition. Previously, we have proposed that the obese rat's
hyperphagia
arises from rapid adipocyte filling. Since high-fat diets facilitate adipocyte enlargement, the early "breakpoint" of
hyperphagia
seen with the high-fat diet may indicate that this feeding stimulation decreases as the fat cells of the obese rat approach maximal size.
...
PMID:Diet composition determines course of hyperphagia in developing Zucker obese rats. 208 11
These studies were undertaken to assess the effects of increased
galactose
(v increased glucose) metabolism via the polyol pathway on vascular filtration function in the kidneys, eyes, nerves, and aorta. Quantitative radiolabeled tracer techniques were used to assess glomerular filtration rate (GFR) and regional tissue vascular clearance of plasma 131I-bovine serum albumin (BSA) in five groups of male Sprague-Dawley rats: nondiabetic controls, streptozotocin-diabetic rats, nondiabetic rats fed a 50%
galactose
diet, diabetic rats treated with sorbinil (an aldose reductase inhibitor), and
galactose
-fed rats treated with sorbinil. Sorbinil was added to the diet to provide a daily dose of approximately .2 mmol/kg body weight. After 2 months of diabetes or
galactose
ingestion, albumin clearance was increased twofold to fourfold in the eye (anterior uvea, choroid, and retina), sciatic nerve, aorta, and kidney; GFR was increased approximately twofold and urinary excretion of endogenous albumin and IgG were increased approximately 10-fold. Sorbinil treatment markedly reduced or completely prevented all of these changes in
galactose
-fed, as well as in diabetic rats. These observations support the hypothesis that increased metabolism of glucose via the sorbitol pathway is of central importance in mediating virtually all of the early changes in vascular filtration function associated with diabetes in the kidney, as well as in the eyes, nerves, and aorta. On the other hand, renal hypertrophy in diabetic rats and polyuria,
hyperphagia
, and impaired weight gain in
galactose
-fed and in diabetic rats were unaffected by sorbinil and therefore are unlikely to be mediated by increased polyol metabolism.
...
PMID:Vascular filtration function in galactose-fed versus diabetic rats: the role of polyol pathway activity. 211 13
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>